Display Settings:

Format

Send to:

Choose Destination

    Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S25-34.

    Vancomycin resistance in gram-positive cocci.

    Courvalin P.

    Unite des Agents Antibacteriens, Institut Pasteur, Paris, France. pcourval@pasteur.fr

    The first vancomycin-resistant clinical isolates of Enterococcus species were reported in Europe in 1988. Similar strains were later detected in hospitals on the East Coast of the United States. Since then, vancomycin-resistant enterococci have spread with unexpected rapidity and are now encountered in hospitals in most countries. This article reviews the mode of action and the mechanism of bacterial resistance to glycopeptides, as exemplified by the VanA type, which is mediated by transposon Tn1546 and is widely spread in enterococci. The diversity, regulation, evolution, and recent dissemination of methicillin-resistant Staphylococcus aureus are then discussed.

    PMID: 16323116 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Vancomycin (Vancocin®)

      Vancomycin is used to treat colitis (inflammation of the intestine caused by certain bacteria) that may occur after antibiotic treatment. Vancomycin is in a class of medications called glycopeptide antibiotics. It works ...